Emerging Agents and Combinations to Treat RET Fusion-Positive Lung Cancers

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

REThink Treatment of NSCLC: Optimizing Care Through Early Genomic Testing and Targeted Treatment

Emerging Agents and Combinations to Treat RET Fusion-Positive Lung Cancers

ReachMD Healthcare Image
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
  • Overview

    This program discusses rapidly evolving advances regarding early genomic profiling for NSCLC patients including detection of RET fusion/alterations and efficacy/safety of approved selective RET-targeted therapies for RET-positive NSCLC. Learners will be better prepared to integrate these options into individualized treatment plans in their clinical practice and address associated adverse events (AEs).

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including medical oncologists, thoracic oncologists, pathologists, pulmonologists, clinical pharmacists, oncology nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of patients with lung cancer.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Employ genomic testing for all NSCLC patients to identify those with actionable alterations who may benefit from a selective RET inhibitor
    • Assess new and emerging outcomes data, evidence, and updated guidelines for targeted therapies to inform frontline treatment strategies for RET-positive NSCLC
    • Prepare management strategies for any associated AEs in patients with RET-positive NSCLC
  • Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

  • Faculty Disclosure of Commercial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs. 

    The following faculty have disclosed:

    Alexander Drilon, MD, faculty for this educational event, received honoraria and advisory board fees from Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, Abbvie, 14ner/Elevation Oncology, ArcherDX, Monopteros, Novartis, EMD Serono, Medendi, Repare RX, Nuvalent, Merus, Chugai Pharmaceutical, Remedica Ltd, mBrace, AXIS, EPG Health, Harborside Nexus, Liberum, RV More, Ology, Amgen, TouchIME, Janssen, Entos, Treeline Bio, Prelude, Applied Pharmaceutical Science, Inc, AiCME, I3 Health, MonteRosa, Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, Peerview Institute, Paradigm Medical Communications, WebMD, MJH Life Sciences, Med Learning, Imedex, Answers in CME, Clinical Care Options, JNCC/Harborside, and Lungevity ; and is a patent holder for TreelineBio; and receives research funds from Pfizer, Exelixis, GlaxoSmithKlein, Teva, Taiho, PharmaMar, Selpercatinib-Osimertinib (filed/pending), and Foundation Medicine and; receives royalties from Wolters Kluwer. 

    Justin Gainor, MD, faculty for this educational event, received an honorarium and advisory fees from Pfizer, Novartis, Takeda, AstraZeneca, Merck, Gilead, Genentech/Roche, Bristol-Myers Squibb, Ariad/Takeda, Genentech/Roche, Loxo/Lilly, Mirati, Moderna, Blueprint, Amgen, Agios, Regeneron, Oncorus, GlydeBio, iTeos, Karyopharm, Roche, and Takeda; and received research funds from Novartis, Genentech, Takeda, Tesaro, Moderna, Blueprint, Bristol-Myers Squibb, Jounce, Array Biopharma, Adaptimmune, Novartis, Alexo, and Merck; and received ownership interest from Ironwood Pharmaceuticals (Immediate family member). 

  • Planners and Managers Disclosure List

    The following planners/reviewers/managers have disclosed:

    Robert Garris, PharmD, MPH, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

    TotalCME, Inc. planners and managers have no relevant commercial relationships to disclose.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by independent educational grants from Blueprint Medicines and Genentech, a member of the Roche Group. 

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

  • Fee Statement

    This activity is FREE to all participants.

  • Instructions for Completion

    During the period 12/07/2022 through 12/07/2023, registered participants wishing to receive continuing education credit for this activity must follow these steps:

    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule29 Sep 2023